Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker.
Takawa M, Masuda K, Kunizaki M, Daigo Y, Takagi K, Iwai Y, Cho HS, Toyokawa G, Yamane Y, Maejima K, Field HI, Kobayashi T, Akasu T, Sugiyama M, Tsuchiya E, Atomi Y, Ponder BA, Nakamura Y, Hamamoto R.
Takawa M, et al. Among authors: hamamoto r.
Cancer Sci. 2011 Jul;102(7):1298-305. doi: 10.1111/j.1349-7006.2011.01958.x. Epub 2011 May 26.
Cancer Sci. 2011.
PMID: 21539681
Free PMC article.